Compare SNDX & MUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | MUX |
|---|---|---|
| Founded | 2005 | 1979 |
| Country | United States | Canada |
| Employees | N/A | 1432 |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2014 | N/A |
| Metric | SNDX | MUX |
|---|---|---|
| Price | $19.31 | $19.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $38.69 | $26.63 |
| AVG Volume (30 Days) | ★ 1.5M | 986.0K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $172,352,000.00 | N/A |
| Revenue This Year | $107.19 | $37.86 |
| Revenue Next Year | $41.88 | $31.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 627.84 | N/A |
| 52 Week Low | $8.59 | $9.04 |
| 52 Week High | $25.59 | $29.70 |
| Indicator | SNDX | MUX |
|---|---|---|
| Relative Strength Index (RSI) | 53.41 | 42.92 |
| Support Level | $19.28 | $17.65 |
| Resistance Level | $22.40 | $20.59 |
| Average True Range (ATR) | 0.82 | 1.15 |
| MACD | 0.25 | 0.05 |
| Stochastic Oscillator | 75.74 | 38.29 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.